Murali Yallapu to Carcinoma, Pancreatic Ductal
This is a "connection" page, showing publications Murali Yallapu has written about Carcinoma, Pancreatic Ductal.
Connection Strength
0.672
-
Dhasmana A, Dhasmana S, Kotnala S, Laskar P, Khan S, Haque S, Jaggi M, Yallapu MM, Chauhan SC. CEACAM7 expression contributes to early events of pancreatic cancer. J Adv Res. 2024 01; 55:61-72.
Score: 0.182
-
Kumari S, Khan S, Sekhri R, Mandil H, Behrman S, Yallapu MM, Chauhan SC, Jaggi M. Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. Br J Cancer. 2020 01; 122(1):121-131.
Score: 0.146
-
Khan S, Zafar N, Khan SS, Setua S, Behrman SW, Stiles ZE, Yallapu MM, Sahay P, Ghimire H, Ise T, Nagata S, Wang L, Wan JY, Pradhan P, Jaggi M, Chauhan SC. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. HPB (Oxford). 2018 06; 20(6):563-572.
Score: 0.128
-
Khan S, Sikander M, Ebeling MC, Ganju A, Kumari S, Yallapu MM, Hafeez BB, Ise T, Nagata S, Zafar N, Behrman SW, Wan JY, Ghimire HM, Sahay P, Pradhan P, Chauhan SC, Jaggi M. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. Oncogene. 2017 01 26; 36(4):491-500.
Score: 0.115
-
Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, Yacoubian AM, Behrman SW, Zafar N, Kumar D, Thompson PA, Jaggi M, Chauhan SC. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Oncotarget. 2014 Sep 15; 5(17):7599-609.
Score: 0.102